GSK3B and diabetes mellitus: Consistently, our western blot results revealed considerable inhibition of GSK-3β activity in DM rats as reflected by the decreased phosphorylated form of GSK-3β, and downregulation of β-catenin expression as well (Fig. 6A,B).